Company profile: GeneCentric Therapeutics
1.1 - Company Overview
Company description
- Provider of molecular diagnostic tests and RNA-based informatics for oncology, including rT(I)ME Explorer for therapy-selective gene signatures, PurIST for PDAC subtyping, FGFR-PRS for identifying FGFR inhibitor candidates in urothelial cancer, AF-PRS for NSCLC chemotherapy prognosis, ICI-PRS for immune checkpoint inhibitor response prediction, and rADIO for antigen discovery and immunotherapy biomarkers.
Products and services
- AF-PRS: A 48-gene RNA expression assay that classifies NSCLC lung adenocarcinoma subtypes linked to prognosis on pemetrexed/platinum doublet chemotherapy to inform treatment selection
- ICI-PRS: A predictive multi-feature signature that evaluates immunotherapy candidacy by complementing TMB and outperforming PD-L1 biomarker tests to refine immune checkpoint inhibitor treatment decisions
- RT(I)ME Explorer Platform: An RNA-based informatics system that develops gene signatures and diagnostics to match patients to the right cancer therapy, enhancing precise patient selection
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to GeneCentric Therapeutics
Cellmark
HQ: United Kingdom
Website
- Description: Provider of DNA testing services, specializing in DNA analysis, paternity testing, and hair drug and alcohol testing, among others.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellmark company profile →
Redpin Therapeutics
HQ: United States
Website
- Description: Provider of a preclinical-stage gene therapy platform developing proprietary chemogenetics for targeted cell therapies to address currently intractable diseases of the nervous system, integrating principles from synthetic biology, gene therapy, and traditional pharmacotherapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Redpin Therapeutics company profile →
GeneInsight
HQ: United States
Website
- Description: Provider of an IT platform that streamlines data interpretation and management; GeneInsight Suite has been in clinical use and evolving since 2005, developed at Partners HealthCare in collaboration with leading geneticists, laboratory operations personnel, practicing physicians, and IT professionals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GeneInsight company profile →
Delfi Diagnostics
HQ: United States
Website
- Description: Provider of high-precision, non-invasive blood tests for early cancer detection, including the FirstLook Lung test using DNA fragment patterns; leverages machine learning and fragmentomics to analyze cell-free DNA fragments; and runs the CASCADE-LUNG clinical study to validate blood-based lung cancer screening technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Delfi Diagnostics company profile →
Iveric Bio
HQ: United States
Website
- Description: Provider of science-driven biopharmaceutical research and development focused on novel treatment options for retinal diseases with significant unmet medical needs, including age-related macular degeneration, developing therapeutic product candidates for age-related retinal diseases and gene therapy product candidates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iveric Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for GeneCentric Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to GeneCentric Therapeutics
2.2 - Growth funds investing in similar companies to GeneCentric Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for GeneCentric Therapeutics
4.2 - Public trading comparable groups for GeneCentric Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →